Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

1.1K
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
1.1K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.0K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

686
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
686
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

278
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
278
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

293
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
293
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

252
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
252

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Suprachoroidal Triamcinolone Acetonide for the Treatment of Refractory Macular Edema Secondary to Non-Infectious Uveitis.

Pharmaceutics·2026
Same author

Toxoplasmosis meets the World Health Organization criteria for a neglected tropical disease.

PLoS neglected tropical diseases·2026
Same author

Exogenous Fusarium Endophthalmitis: Clinical Features, Treatment Modalities, and Visual Outcomes.

Investigative ophthalmology & visual science·2026
Same author

Clinical efficacy and safety of aflibercept biosimilars in neovascular age-related macular degeneration: a systematic review and meta-analysis of randomised controlled trials.

The British journal of ophthalmology·2026
Same author

Culture-proven endogenous endophthalmitis: ocular and systemic clinical features and outcomes.

Journal of ophthalmic inflammation and infection·2026
Same author

RWC Update: Modern One Health Approaches to Novel Challenges in Infectious Uveitis-Parasitic, Fungal and Mycobacterial Uveitis (Part 2); Management of 180° Iridodialysis With Aphakia and Total Hyphema; Retinal Astrocytic Hamartoma.

Ophthalmic surgery, lasers & imaging retina·2026
Same journal

Prognostic Value of Interocular Flicker ERG Asymmetry in Acute Postoperative Endophthalmitis After Intraocular Surgery: A Pilot Study.

Journal of ophthalmology·2026
Same journal

Clinical Ophthalmology Consultations in Paediatric Inpatient Rehabilitation-A Retrospective Case-Note Analysis.

Journal of ophthalmology·2026
Same journal

Pathogenesis of Neovascular Glaucoma in Diabetic Retinopathy: A Review.

Journal of ophthalmology·2026
Same journal

Mathematical Modeling of IOL Power Changes After Pupil Dilation Based on Multifactorial Analysis.

Journal of ophthalmology·2026
Same journal

Reduced Neutrophil-to-Eosinophil Ratio in Chronic Dacryocystitis: A Hematological Clue to Allergic Pathogenesis.

Journal of ophthalmology·2026
Same journal

Comparative Topographic and Tomographic Assessment of Post-LASIK Corneal Ectasia.

Journal of ophthalmology·2026
See all related articles

Related Experiment Video

Updated: Apr 25, 2026

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

2.0K

Sustained-release corticosteroid options.

Mariana Cabrera1, Steven Yeh2, Thomas A Albini1

  • 1Department of Ophthalmology, University of Miami Miller School of Medicine, Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL 33136, USA.

Journal of Ophthalmology
|August 21, 2014
PubMed
Summary
This summary is machine-generated.

Sustained-release corticosteroid implants offer new treatment options for macular edema and uveitis. This summary reviews current clinical knowledge on Ozurdex, Retisert, and Iluvien implants.

More Related Videos

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

10.7K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

30.6K

Related Experiment Videos

Last Updated: Apr 25, 2026

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

2.0K
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

10.7K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

30.6K

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Macular edema from diabetes and retinal vein occlusion, and noninfectious posterior uveitis are significant causes of vision loss.
  • Sustained-release corticosteroid therapy presents a promising treatment strategy for these conditions.

Purpose of the Study:

  • To summarize current clinical knowledge on available sustained-release corticosteroid implants.
  • To compare the characteristics and indications of Ozurdex, Retisert, and Iluvien.

Main Methods:

  • Review of current clinical literature on sustained-release corticosteroid implants.
  • Comparative analysis of implant characteristics, duration of effect, and approved indications.

Main Results:

  • Three sustained-release corticosteroid implants are available: Ozurdex (dexamethasone), Retisert (fluocinolone acetonide), and Iluvien (fluocinolone acetonide).
  • These implants differ in physical characteristics, duration of action, and approved clinical indications.

Conclusions:

  • Clinicians have diverse sustained-release corticosteroid implant options for treating specific ophthalmic conditions.
  • Understanding the unique profiles of each implant is crucial for optimal patient management.